Cite
HARVARD Citation
Borte, M. et al. (n.d.). Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. Clinical and experimental immunology. pp. 146-159. [Online].